Login to Your Account



Happier ASCO News Due As Avastin Data Take Center Stage

By Randall Osborne


Monday, May 26, 2003

Among the headliners at the upcoming meeting of the American Society of Clinical Oncology are details on the eye-opening success of Genentech Inc.'s vascular endothelial growth factor drug Avastin (bevacizumab) in Phase III trials for metastatic colorectal cancer and long-awaited word regarding scandal-plagued ImClone System Inc.'s cancer drug Erbitux.

But that's hardly all.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription